You are here

Nat Commun DOI:10.1038/ncomms6352

A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations.

Publication TypeJournal Article
Year of Publication2014
AuthorsDickinson, BC, Packer, MS, Badran, AH, Liu, DR
JournalNat Commun
Volume5
Pages5352
Date Published2014 Oct 30
ISSN2041-1723
KeywordsAmino Acid Sequence, Bacteriophage M13, Drug Resistance, Viral, Evolution, Molecular, Gene Expression, Genetic Techniques, Hepacivirus, Humans, Isoquinolines, Lactams, Molecular Sequence Data, Mutation, Peptide Hydrolases, Protease Inhibitors, Sulfonamides, Viral Proteins
Abstract

The laboratory evolution of protease enzymes has the potential to generate proteases with therapeutically relevant specificities and to assess the vulnerability of protease inhibitor drug candidates to the evolution of drug resistance. Here we describe a system for the continuous directed evolution of proteases using phage-assisted continuous evolution (PACE) that links the proteolysis of a target peptide to phage propagation through a protease-activated RNA polymerase (PA-RNAP). We use protease PACE in the presence of danoprevir or asunaprevir, two hepatitis C virus (HCV) protease inhibitor drug candidates in clinical trials, to continuously evolve HCV protease variants that exhibit up to 30-fold drug resistance in only 1 to 3 days of PACE. The predominant mutations evolved during PACE are mutations observed to arise in human patients treated with danoprevir or asunaprevir, demonstrating that protease PACE can rapidly identify the vulnerabilities of drug candidates to the evolution of clinically relevant drug resistance.

DOI10.1038/ncomms6352
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/25355134?dopt=Abstract

Alternate JournalNat Commun
PubMed ID25355134
PubMed Central IDPMC4215169
Grant List / / Howard Hughes Medical Institute / United States
T32 GM008313 / GM / NIGMS NIH HHS / United States